

BACKGROUND

1. About Boehringer Ingelheim
2. Boehringer Ingelheim's commitment to cancer
3. Research and development in cancer treatments

1. ABOUT BOEHRINGER INGELHEIM

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates and more than 47,400 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.



Taking social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative "Making more Health" and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability.

In 2013, Boehringer Ingelheim achieved net sales of about 14.1 billion euros. R&D expenditure corresponds to 19.5% of its net sales.

2. BOEHRINGER INGELHEIM'S COMMITMENT TO CANCER

Cancer is a major global public health problem and despite considerable advances in disease awareness, diagnosis and treatment, it remains an area of significant unmet medical need. As a research-driven pharmaceutical group of companies, Boehringer Ingelheim has a long-term commitment to deliver innovative cancer therapies by discovering and developing novel treatment options, both New Chemical Entities (NCEs) and New Biological Entities (NBEs), that combine ground-breaking science with high therapeutic value for patients.

The company is applying its scientific discoveries and research advances in cancer biology to develop a wide range of novel therapies in areas of unmet medical need in both solid tumours and haematological malignancies.

More than 400 employees around the world are dedicated to the discovery and development of new cancer treatments: approximately 250 highly skilled and motivated scientists in Vienna, Austria at the dedicated, state-of-the-art Boehringer Ingelheim cancer research centre and more than 200 across the globe associated with oncology research and development.

They join forces with the Research Institute of Molecular Pathology (IMP) in Austria and experts in cancer research and medicine at universities and hospitals around the world,

*Afatinib is approved in a number of markets, including the EU, Japan, Taiwan and Canada under the brand name GIOTRIF® and in the U.S. under the brand name GILOTRIF™ for specific types of EGFR mutated NSCLC. Afatinib is under regulatory review by health authorities in other countries worldwide. Nintedanib and volasertib are investigational compounds and are not yet approved. Their safety and efficacy have not yet been fully established.

BACKGROUND

to focus on developing a broad range of breakthrough next generation products to combat cancer.

Boehringer Ingelheim is committed to the clinical development of pioneering treatments for cancer through an extensive and diverse global study programme involving investigators and patients from around the world. This is supported by a significant financial investment from Boehringer Ingelheim, with the aim of developing treatments, which will make a difference to the lives of patients and their families.

3. RESEARCH AND DEVELOPMENT IN CANCER TREATMENTS

Boehringer Ingelheim is using its significant resources to actively develop targeted therapies based on biologicals and small molecules in areas of unmet medical need including both solid and haematological cancers. Cutting-edge research conducted at Boehringer Ingelheim's research centre in Vienna and the Research Institute of Molecular Pathology (IMP) has resulted in several promising compounds.



Using technological advances and breakthrough science, the search for new cancer treatments is currently focused on three areas:

- Signal transduction inhibition with afatinib*, an irreversible ErbB Family Blocker. Afatinib* (GIOTRIF® / GILOTRIF®) is indicated for the treatment of distinct types of EGFR mutation-positive NSCLC. Afatinib is approved in a number of markets, including the EU, Japan, Taiwan and Canada under the brand name GIOTRIF® and in the U.S. under the brand name GILOTRIF®. It is under regulatory review in other countries. Phase III trials in squamous head and neck cancer (HNSCC) and trials in other tumour types are ongoing
- Angiogenesis inhibition with the compound nintedanib*
- Cell-cycle kinase inhibition with the compound volasertib*

These compounds are being investigated to evaluate their potential to be effective in patients who are resistant to existing treatments, to improve the efficacy of established drugs in combination regimens, and to provide targeted therapies with more favourable tolerability profiles.

The Boehringer Ingelheim oncology pipeline covers a broad range of solid tumours and haemato-oncologic indications.

*Afatinib is approved in a number of markets, including the EU, Japan, Taiwan and Canada under the brand name GIOTRIF® and in the U.S. under the brand name GILOTRIF™ for specific types of EGFR mutated NSCLC. Afatinib is under regulatory review by health authorities in other countries worldwide. Nintedanib and volasertib are investigational compounds and are not yet approved. Their safety and efficacy have not yet been fully established.